Nasdaq · CIK 0001759138
CABA Cabaletta Bio, Inc.
Insider trading from SEC Form 4. Last filing Jun 10, 2026. Close $1.93 on Oct 9, 2026, +2% from the 52-week low and -53% from the high.
In brief
Cabaletta Bio, Inc. (CABA) has 45 SEC Form 4 filings on file from 12 insiders, the latest filed on Jun 10, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
11 open-market trades have been scored at CABA. The newest: Gwendolyn Binder (President, Science & Tech.) bought $25k of stock on Jan 21, 2026, filed Jan 21, 2026, scored 45 (moderate). The largest of the 11 shown: Gwendolyn Binder (See Remarks) sold $241k on Dec 19, 2023, scored 3 (weak), under a 10b5-1 plan. 8 insiders bought within 14 days of each other around Jan 21, 2026.
2 Form 144 notices of planned sales are on file, the latest filed Nov 20, 2023.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cabaletta Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Gwendolyn Binder President, Science & Tech. buy | $25k 11,312 shares | +57% | - | |
| 40Moderate | Catherine Bollard director buy | $9,982 4,405 shares | +441% | - | |
| 38Weak | Michael Gerard General Counsel buy | $15k 6,600 shares | - | - | |
| 38Weak | Mark Simon director buy | $25k 11,061 shares | +8% | - | |
| 50Moderate | Steven Nichtberger President & CEO buy | $101k 45,000 shares | +5% | - | |
| 45Moderate | Steve Gavel Chief Commercial Officer buy | $50k 22,170 shares | - | - | |
| 45Moderate | Shawn Tomasello director buy | $50k 22,725 shares | - | - | |
| 38Weak | David J. Chang Chief Medical Officer buy | $20k 8,800 shares | - | - | |
| 3Weak | Gwendolyn Binder See Remarks sell | $241k 11,000 shares | -35% | +259% from low0% from high | |
| 2Weak | Gwendolyn Binder See Remarks sell | $196k 11,000 shares | -35% | +436% from low-4% from high | |
| 1Weak | Gwendolyn Binder See Remarks sell | $147k 11,000 shares | -35% | +916% from low-29% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 20, 2023 | GWENDOLYN BINDER Officer | 33,000 0.08% of outstanding | $593k | Nov 20, 2023 | $488k |
| Oct 19, 2023 | GWENDOLYN BINDER Officer | 11,000 0.03% of outstanding | $148k | Oct 19, 2023 | $341k |
Transactions
The newest 50 of 147 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Shawn Tomasello director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 10, 2026 |
| Jun 9, 2026 | Catherine Bollard director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 10, 2026 |
| Jun 9, 2026 | Scott C. Brun director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 10, 2026 |
| Jun 9, 2026 | Mark Simon director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 10, 2026 |
| Jun 9, 2026 | Richard C Henriques Jr director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 10, 2026 |
| Mar 2, 2026 | Arun Das Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 2, 2026 |
| Mar 2, 2026 | Gwendolyn Binder President, Science & Tech. | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 2, 2026 |
| Mar 2, 2026 | Michael Gerard General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 2, 2026 |
| Mar 2, 2026 | David J. Chang Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 2, 2026 |
| Mar 2, 2026 | Steven Nichtberger President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +674,000 | $0.00 | $0 | 674,000 | Mar 2, 2026 |
| Mar 2, 2026 | Anup Marda Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 2, 2026 |
| Jan 21, 2026 | Steven Nichtberger President & CEO | POpen-market purchase Common Stock | +45,000 | $2.24 | $101k | 1,031,483 | Jan 21, 2026 |
| Jan 21, 2026 | Steve Gavel Chief Commercial Officer | POpen-market purchase Common Stock | +22,170 | $2.27 | $50k | 22,170 | Jan 21, 2026 |
| Jan 21, 2026 | Shawn Tomasello director | POpen-market purchase Common Stockindirect: By Shawn Tomasello Consulting LLC | +22,725 | $2.21 | $50k | 22,725 | Jan 21, 2026 |
| Jan 21, 2026 | David J. Chang Chief Medical Officer | POpen-market purchase Common Stock | +8,800 | $2.26 | $20k | 8,800 | Jan 21, 2026 |
| Jan 21, 2026 | Gwendolyn Binder President, Science & Tech. | POpen-market purchase Common Stock | +11,312 | $2.19 | $25k | 31,312 | Jan 21, 2026 |
| Jan 21, 2026 | Catherine Bollard director | POpen-market purchase Common Stock | +4,405 | $2.27 | $9,982 | 5,405 | Jan 21, 2026 |
| Jan 21, 2026 | Michael Gerard General Counsel | POpen-market purchase Common Stock | +6,600 | $2.27 | $15k | 6,600 | Jan 21, 2026 |
| Jan 21, 2026 | Mark Simon director | POpen-market purchase Common Stock | +11,061 | $2.28 | $25k | 147,205 | Jan 21, 2026 |
| Oct 13, 2025 | Steve Gavel CHIEF COMMERCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Oct 15, 2025 |
| Jun 9, 2025 | Mark Simon director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 9, 2025 | Shawn Tomasello director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 9, 2025 | Catherine Bollard director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 9, 2025 | Scott C. Brun director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 9, 2025 | Richard C Henriques Jr director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| May 19, 2025 | Shawn Tomasello director | DDisposition to issuer Stock Option (Right to Buy)derivative | -44,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Catherine Bollard director | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,428 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | David J. Chang Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -185,709 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Scott C. Brun director | DDisposition to issuer Stock Option (Right to Buy)derivative | -44,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Richard C Henriques Jr director | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,428 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Steven Nichtberger President & CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -99,714 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Michael Gerard General Counsel | DDisposition to issuer Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Gwendolyn Binder President, Science & Tech. | DDisposition to issuer Stock Option (Right to Buy)derivative | -66,667 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Anup Marda Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -139,282 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Mark Simon director | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,460 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Arun Das Chief Business Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,416 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | David J. Chang Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +185,709 | $0.00 | $0 | 185,709 | May 19, 2025 |
| May 19, 2025 | Catherine Bollard director | AGrant or award Stock Option (Right to Buy)derivative | +46,428 | $0.00 | $0 | 46,428 | May 19, 2025 |
| May 19, 2025 | Anup Marda Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +139,282 | $0.00 | $0 | 139,282 | May 19, 2025 |
| May 19, 2025 | Arun Das Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +18,416 | $0.00 | $0 | 18,416 | May 19, 2025 |
| May 19, 2025 | Shawn Tomasello director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | May 19, 2025 |
| May 19, 2025 | Mark Simon director | AGrant or award Stock Option (Right to Buy)derivative | +18,460 | $0.00 | $0 | 18,460 | May 19, 2025 |
| May 19, 2025 | Scott C. Brun director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | May 19, 2025 |
| May 19, 2025 | Steven Nichtberger President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +99,714 | $0.00 | $0 | 99,714 | May 19, 2025 |
| May 19, 2025 | Michael Gerard General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | May 19, 2025 |
| May 19, 2025 | Richard C Henriques Jr director | AGrant or award Stock Option (Right to Buy)derivative | +46,428 | $0.00 | $0 | 46,428 | May 19, 2025 |
| May 19, 2025 | Gwendolyn Binder President, Science & Tech. | AGrant or award Stock Option (Right to Buy)derivative | +66,667 | $0.00 | $0 | 66,667 | May 19, 2025 |
| May 19, 2025 | Catherine Bollard director | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | David J. Chang Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -48,836 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | Scott C. Brun director | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | May 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Gwendolyn BinderSee Remarks
- Catherine Bollarddirector
- Scott C. Brundirector
- David J. ChangChief Medical Officer
- Arun DasChief Business Officer
- Steve GavelChief Commercial Officer
- Michael GerardGeneral Counsel
- Richard C Henriques Jrdirector
- Anup MardaChief Financial Officer
- Steven NichtbergerPresident & CEO
- Mark Simondirector
- Shawn Tomasellodirector
Questions about CABA
Answered from the filings on this page, as of the latest one.
Are insiders buying CABA?
No. In the last 90 days no insider at Cabaletta Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CABA on the open market?
Gwendolyn Binder (President, Science & Tech.) bought $25k of CABA on Jan 21, 2026 and filed the Form 4 on Jan 21, 2026. InsiderTell scored 45 (moderate), with 8 insiders on the same side within 14 days.
How many insiders file Form 4 at Cabaletta Bio, Inc.?
12 people have filed a Form 4 at Cabaletta Bio, Inc., among them Gwendolyn Binder (See Remarks), Catherine Bollard (director), Scott C. Brun (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.